share_log

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

Benzinga Real-time News ·  Sep 15, 2021 06:08

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment